GSK Strikes up to $2 Billion Deal to Acquire Boston Pharmaceuticals' Liver Disease Drug Candidate
GSK (GSK) on Wednesday agreed to acquire Boston Pharmaceuticals' steatotic liver disease therapeutic
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Terms and Privacy Policy